Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

6/24/24 11:26:29 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EFTR alert in real time by email

EFFECTOR Therapeutics Inc (NASDAQ:EFTR) shares are trading lower by 75% to $0.28 during Monday’s session after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq.

This decision follows a special board meeting and the company expects delisting soon. Craig R. Jalbert, who the company says is experienced in managing distressed businesses, has been appointed as the new CEO, President, Treasurer, Secretary and sole board member to oversee the wind-down process.

According to data from Benzinga Pro, EFTR has a 52-week high of $22.50 and a 52-week low of $0.27.

Get the next $EFTR alert in real time by email

Date	Price Target	Rating	Analyst
1/25/2022	$20.00 → $16.00	Outperform	Credit Suisse
1/25/2022	$20.00 → $6.20	Buy → Hold	Stifel
1/25/2022	$33.00 → $8.00	Market Outperform	JMP Securities
11/9/2021	$20.00	Hold → Buy	Stifel
10/12/2021	$20.00	Outperform	Credit Suisse
10/4/2021	$20.00	Buy	Mizuho
9/21/2021	$33.00	Market Outperform	JMP Securities
9/20/2021	$20.00	Hold	Stifel

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

Chat with this insight

Recent Analyst Ratings for $EFTR

$EFTR Financials

Live finance-specific insights

eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

$EFTR SEC Filings

SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

$EFTR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Credit Suisse reiterated coverage on eFFECTOR Therapeutics with a new price target

eFFECTOR Therapeutics downgraded by Stifel with a new price target

JMP Securities reiterated coverage on eFFECTOR Therapeutics with a new price target

$EFTR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Loewy Caroline M

SEC Form 4 filed by Director Klencke Barbara

SEC Form 4 filed by Director Ehrlich Christopher B

$EFTR Press Releases

Fastest customizable press release news feed in the world

$EFTR Large Ownership Changes

This live feed shows all institutional transactions in real time.

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

SEC Form SC 13D/A filed by eFFECTOR Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

$EFTR Market Insights

Live Market Insights

eFFECTOR Therapeutics Declared in Default on $75M Oxford Finance Loan

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

$EFTR Leadership Updates

Live Leadership Updates

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$EFTR

$EFTR
Financials

$EFTR
SEC Filings

$EFTR
Analyst Ratings

$EFTR
Insider Trading

$EFTR
Press Releases

$EFTR
Large Ownership Changes

$EFTR
Market Insights

$EFTR
Leadership Updates